FFO
LRMR icon

Fortitude Family Office’s Larimar Therapeutics LRMR Stock Holding History

Fortitude Family Office’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$666 Buy
+148
New +$592 ﹤0.01% 1623

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fortitude Family Office's LRMR Position: Q1 2026 in Review

Fortitude Family Office opened a new position in Larimar Therapeutics (LRMR) in Q1 2026: 148 shares worth $666. The stake represents ﹤0.01% of the portfolio and ranks #1623 among its holdings.

162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Fortitude Family Office held 148 shares of Larimar Therapeutics worth $666 as of Q1 2026.
  • Larimar Therapeutics was a new Fortitude Family Office position in Q1 2026.
  • Larimar Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #1623 holding.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.